当前蛋白身份:S6C4S0 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
4O58 Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/3/1975 (H3N2) influenza hemagglutinin 提交 2013-12-19 Assembly 1 其他组合 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 H 161–245(85 aa) 片段:Fab F045-092 heavy chain
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 SO4 SULFATE ION × 42 PEG DI(HYDROXYETHYL)ETHER × 9 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.1;277 K;1.7 M ammonium sulfate, 0.1 M Tris pH 8.1, 4% PEG 400, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 2.75 Å R-free 0.224
4O5I Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/361/2011 (H3N2) influenza hemagglutinin 提交 2013-12-19 Assembly 1 其他组合 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 M 161–245(85 aa) 片段:Fab F045-092 heavy chain
链 O 161–245(85 aa) 片段:Fab F045-092 heavy chain
链 Q 161–245(85 aa) 片段:Fab F045-092 heavy chain
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;20% PEG 400, 30% 1,2-propanediol, 0.1 M HEPES pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
分辨率 6.50 Å R-free 0.248
4O5I Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/361/2011 (H3N2) influenza hemagglutinin 提交 2013-12-19 Assembly 2 其他组合 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 S 161–245(85 aa) 片段:Fab F045-092 heavy chain
链 U 161–245(85 aa) 片段:Fab F045-092 heavy chain
链 W 161–245(85 aa) 片段:Fab F045-092 heavy chain
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;20% PEG 400, 30% 1,2-propanediol, 0.1 M HEPES pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
分辨率 6.50 Å R-free 0.248
5UGY Influenza hemagglutinin in complex with a neutralizing antibody 提交 2017-01-10 Assembly 1 其他组合 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 H 138–243(106 aa) 片段:Fab
链 I 138–243(106 aa) 片段:Fab
链 J 138–243(106 aa) 片段:Fab
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;291 K;2.2 M ammonium sulfate, 100 mM Tris, 5% PEG400, pH 7.5
分辨率 2.80 Å R-free 0.289
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 1 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 G 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 2 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 3 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 K 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 4 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 Q 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 5 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 O 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
5W08 A/Texas/50/2012(H3N2) Influenza hemagglutinin in complex with K03.12 Fab 提交 2017-05-30 Assembly 6 其他组合 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 M 143–247(105 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;291.15 K;100 mM sodium citrate/citric acid, pH 5.5, 20% w/v PEG3000
分辨率 2.60 Å R-free 0.262
6CBJ Crystal Structure of DH270.3 Fab in complex with Man9 提交 2018-02-03 Assembly 1 其他组合 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 H 143–247(105 aa)
未记录 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;1 M sodium/potassium phosphate, pH 5.6
分辨率 2.85 Å R-free 0.231
6MYY Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer, 3 Fabs bound, sharpened map 提交 2018-11-02 Assembly 1 其他组合 异源复合物;蛋白 × 9 PDB 声明:nonameric(9) 与蛋白数一致
链 D 132–248(117 aa) 片段:germline VH gene reverted sequences of VH1-2*02, which include CDRH1 and CDRH2 along with the mature CDRH3 of VRC01
链 G 132–248(117 aa) 片段:germline VH gene reverted sequences of VH1-2*02, which include CDRH1 and CDRH2 along with the mature CDRH3 of VRC01
链 H 132–248(117 aa) 片段:germline VH gene reverted sequences of VH1-2*02, which include CDRH1 and CDRH2 along with the mature CDRH3 of VRC01
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 12 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.80 Å
6MZJ Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer, 2 Fabs bound, sharpened map 提交 2018-11-05 Assembly 1 其他组合 异源复合物;蛋白 × 7 PDB 声明:heptameric(7) 与蛋白数一致
链 D 132–248(117 aa) 片段:germline VH reverted sequences of VH1-2*02, which include CDRH1 and CDRH2 along with the mature CDRH3 of VRC01
链 H 132–248(117 aa) 片段:germline VH reverted sequences of VH1-2*02, which include CDRH1 and CDRH2 along with the mature CDRH3 of VRC01
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 12 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.80 Å
6UDK HIV-1 bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074 提交 2019-09-19 Assembly 1 其他组合 异源复合物;蛋白 × 18 PDB 声明:octadecameric(18) 与蛋白数一致
链 D 140–249(110 aa)
链 H 140–249(110 aa)
链 M 140–249(110 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 27 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 8
cryo-EM玻璃化条件 冷冻剂 ETHANE;0 blot force, 3.5 second blot time, 3 uL sample added to freshly glow-discharged grids
分辨率 3.90 Å
6UTA Crystal structure of Z004 iGL Fab in complex with ZIKV EDIII 提交 2019-10-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 129–249(121 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;% w/v tryptone, 0.001 M sodium azide, 0.05 M HEPES sodium pH 7.0, 20% w/v polyethylene glycol 3,350
分辨率 3.10 Å R-free 0.291
6UTA Crystal structure of Z004 iGL Fab in complex with ZIKV EDIII 提交 2019-10-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 129–249(121 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;% w/v tryptone, 0.001 M sodium azide, 0.05 M HEPES sodium pH 7.0, 20% w/v polyethylene glycol 3,350
分辨率 3.10 Å R-free 0.291